USP is building a database of counterfeit medicines to support international drug procurement organizations, such as WHO, and the timely sharing of information between national regulators.
In a November 16th article in the In-PharmaTechnologist, Nick Taylor reports on the development of a new database that is due to launch early next year by the US Pharmacopeia (USP).
USP’s database will allow regulators and organizations the ability to monitor counterfeit and substandard drugs and to support more informed enforcement actions and procurement-related decisions.
According to Mr. Taylor’s article:
• Speaking to in-PharmaTechnologist at AAPS 2010 Patrick Lukulay, director of the promoting the quality of medicines (PQM) initiative at USP, outlined how timely sharing of information can support enforcement actions.
• Lukulay said the database could have supported a more effective response to counterfeit medicines that spread to Mali after first being seized in Ghana. Using the database regulators in Mali would have been aware of the products, which had the same batch numbers as the products seized in Ghana, and acted accordingly.
• Having created the architecture the USP is now inputting information about counterfeit or substandard drugs into the database. Listed on the database will be the name of the product, the country it was seized in, what was wrong with it and other descriptors, said Lukulay. If countries agree the database will be shared with the public.
• The benefits of sharing information also underpin the USP's creation of a 'virtual forum'. This will allow users to pose questions, share alerts and discuss best practices among a network of people involved with ensuring the quality of medicines.
Secure Pharma Chain, supports all efforts to share information in fighting the deadly crime of adulterated, fraudulent, substandard and counterfeit drugs.
In a November 16th article in the In-PharmaTechnologist, Nick Taylor reports on the development of a new database that is due to launch early next year by the US Pharmacopeia (USP).
USP’s database will allow regulators and organizations the ability to monitor counterfeit and substandard drugs and to support more informed enforcement actions and procurement-related decisions.
According to Mr. Taylor’s article:
• Speaking to in-PharmaTechnologist at AAPS 2010 Patrick Lukulay, director of the promoting the quality of medicines (PQM) initiative at USP, outlined how timely sharing of information can support enforcement actions.
• Lukulay said the database could have supported a more effective response to counterfeit medicines that spread to Mali after first being seized in Ghana. Using the database regulators in Mali would have been aware of the products, which had the same batch numbers as the products seized in Ghana, and acted accordingly.
• Having created the architecture the USP is now inputting information about counterfeit or substandard drugs into the database. Listed on the database will be the name of the product, the country it was seized in, what was wrong with it and other descriptors, said Lukulay. If countries agree the database will be shared with the public.
• The benefits of sharing information also underpin the USP's creation of a 'virtual forum'. This will allow users to pose questions, share alerts and discuss best practices among a network of people involved with ensuring the quality of medicines.
Secure Pharma Chain, supports all efforts to share information in fighting the deadly crime of adulterated, fraudulent, substandard and counterfeit drugs.
All members of the pharmaceutical supply chain must use all tools including technologies, solutions and cooperative intelligence databases to interdict these dangerous products
It is critical that each member of the supply chain bear the responsibility of securing their inventories in order to protect their business brand and ultimately the health care consumer.
To read the entire story, visit: http://www.in-pharmatechnologist.com/Processing-QC/USP-building-database-of-fake-substandard-meds
It is critical that each member of the supply chain bear the responsibility of securing their inventories in order to protect their business brand and ultimately the health care consumer.
To read the entire story, visit: http://www.in-pharmatechnologist.com/Processing-QC/USP-building-database-of-fake-substandard-meds
To learn more about anti-counterfeiting technologies, visit: http://www.xstreamsystems.net/
Posts
No comments:
Post a Comment